61131-60-0

Basic information

• Product Name: m-(2-nitro-1-propenyl)phenol
• Synonyms: m-(2-nitro-1-propenyl)phenol;3-(2-Nitro-1-propenyl)phenol
• CAS NO: 61131-60-0
• Molecular Formula: C₉H₉NO₃
• Molecular Weight: 179.17266
• EINECS: 262-619-4
• Mol File: 61131-60-0.mol

Chemical Properties

• Boiling Point: 343.3°C at 760 mmHg
• Flash Point: 152.9°C
• Appearance: /
• Density: 1.266g/cm³
• Vapor Pressure: 3.58E-05mmHg at 25°C
• Refractive Index: 1.623
• CAS DataBase Reference: m-(2-nitro-1-propenyl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: m-(2-nitro-1-propenyl)phenol(61131-60-0)
• EPA Substance Registry System: m-(2-nitro-1-propenyl)phenol(61131-60-0)

Safety Data

• Hazardous Substances Data: 61131-60-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H9NO3/c1-7(10(12)13)5-8-3-2-4-9(11)6-8/h2-6,11H,1H3/b7-5+

Upstream product

• 79-24-3 Nitroethane 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 1075-61-2 Desoxy metaraminol 

Relevant articles and documents

Crystal form of L-lysinate of benzopiperidine derivative and preparation method thereof

The invention provides a crystal form of a L-lysinate of a benzopiperidine derivative and a preparation method of the crystal form. Specifically, the invention provides a crystal form II of L-lysinateof (E)-3-(4-((1R, 3R)-2-(4-cyclopropyl phenyl)-6-(1-ethyl-1H-pyrazol-4-yl)-3-methyl-1, 2, 3, 4-tetrahydroisoquinoline-1-yl) phenyl) acrylate and a preparation method of the crystal form II. The crystal form II of the compound shown in the formula (I) has good stability and can be better applied to clinical treatment.

BENZOPIPERIDINE DERIVATIVE, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF

The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description.

TETRAHYDROISOQUINOLINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are tetrahydroisoquinoline compounds with estrogen receptor modulation activity or function having the Formula I structure: I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.